PITTSBURGH, Jan. 8, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the appointment of Adele Gulfo as executive vice president, Global Collaboration and Strategic Operations. Gulfo will serve as a member of Mylan's executive leadership team.
Prior to joining Mylan, Gulfo served as regional president of Latin America in Pfizer's Emerging Markets Business Unit. In this capacity, she led a team of over 4,000 colleagues operating across more than 23 countries. In 2012, under her leadership, the Latin American business achieved more than $3 billion in revenue, making it the largest revenue generator within the Business Unit. Previously, Gulfo served as president and general manager of Pfizer's U.S. Primary Care Business Unit, which included the Managed Markets (Corporate and Government Customer) organization for all of Pfizer's Biopharmaceutical Business Units. In 2011, Pfizer's U.S. Primary Care business generated $13 billion in revenue under her leadership. Earlier in her career at Pfizer, Gulfo was instrumental in the launch of LIPITOR®, which became the world's most successful medicine in terms of sales, and was recognized for developing medical and public education campaigns that helped to establish the significance of lowering cholesterol in preventing and managing heart disease.
Mylan CEO Heather Bresch commented, "Adele's rich and diverse experience in the pharmaceutical industry will bring significant strategic value and leadership to Mylan in numerous areas. For instance, we believe Adele's expertise will support many of our key growth drivers, including our expansion in Latin America, the development and expansion of our global Specialty franchise, and the development of global commercial strategies to maximize our key upcoming launches of increasingly complex generic products, such as in the biologics and respiratory areas. Further, Adele has proven her ability to drive collaboration across and among large, complex organizations in order to leverage capabilities and best practices to drive revenue, and we believe she can support our continued efforts to differentiate Mylan's comprehensive commercial offering to our customers."
Gulfo said, "I had the privilege of collaborating with Mylan during my time at Pfizer, and I am energized both by Mylan's mission to provide high quality medicine to the world's population and by the significant opportunities for growth I see ahead for the company. Mylan brings customers and patients a unique value proposition in terms of its broad product portfolio, vertically-integrated high quality manufacturing platform and expansive global commercial reach. The company's initiatives to leverage these strengths and build on them, for instance through the addition of differentiated products and enhanced services, will further distinguish Mylan from its peers. I look forward to utilizing my expertise and relationships to help execute on this strategy and support Mylan's transformation from a pharmaceutical company into a health care company."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts